FDA-Approved GHRH Analog

Tesamorelin

TH9507 • 44-Amino-Acid GHRH Analog

Tesamorelin is a stabilized GHRH analog that stimulates pituitary growth hormone and IGF-1 release. It is FDA approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

Visceral Fat GH Release Liver Fat Lean Mass

Protocol Snapshot

Quick reference before the deep dive

Verified Vendors

Tesamorelin

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Standard Dose

2mg

Once daily in pivotal clinical trials.

Community Range

1–2mg

Once daily in common off-label protocols.

Class

GHRH Analog

Stimulates endogenous growth-hormone release.

Primary Outcome

Visceral Fat

Measured by CT imaging in controlled trials.

Peptide Grade

GradeA

Regulatory approval, randomized human trials, and a measurable visceral-fat indication provide a strong evidence base, balanced by GH-axis monitoring and metabolic risks.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What Is Tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analog of growth hormone–releasing hormone. It matches the full natural GHRH sequence but includes a trans-3-hexenoic-acid modification that protects it from rapid DPP-4 degradation.

It was FDA approved in 2010 as Egrifta for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Newer Egrifta formulations have updated handling and reconstitution requirements.

Tesamorelin binds GHRH receptors on pituitary somatotroph cells, stimulating a physiological pulse of growth hormone and a gradual rise in IGF-1 while preserving normal feedback through somatostatin.

Why It Is Known for Visceral Fat

Tesamorelin does not selectively bind a visceral-fat receptor. Its reputation comes from clinical trials that specifically measured visceral adipose tissue by CT imaging.

Tesamorelin Benefits

Visceral Fat Reduction

Clinical trials reported approximately 15%–20% reductions in visceral adipose tissue over 26 weeks.

Lean-Mass Preservation

Meta-analysis data reported increased lean body mass while trunk and visceral fat decreased.

Liver Fat

Randomized research in HIV-associated NAFLD reported a substantial reduction in hepatic fat and less fibrosis progression.

Lipid Profile

Trials reported lower triglycerides and an improved total-cholesterol-to-HDL ratio.

Natural GH Pulsatility

Stimulates pituitary GH release while preserving feedback mechanisms rather than supplying exogenous HGH directly.

Recovery & Sleep

Users frequently report improved sleep and recovery after IGF-1 levels stabilize over several weeks.

Protocol Planning

Dosing, cycling, and preparation

Tesamorelin Dosing Protocol

The 2mg daily dose was used in the pivotal clinical trials. Lower 1–2mg off-label protocols are common in peptide communities but have not been validated for general visceral-fat reduction.

Standard Protocol

Dose

2mg once daily

Route

Subcutaneous injection

Timing

30–60 minutes before bed while fasted

Alternative

Fasted morning dose at least 2 hours before food

Duration

Continuous daily dosing in clinical trials

Combined Protocol With Ipamorelin

Tesamorelin

1–2mg

Ipamorelin

100–200mcg

Timing

Pinned together before bed, fasted

Frequency

Daily

Cycle Length

60–90 days

Fasted Timing

Low insulin and higher ghrelin favor a stronger growth-hormone pulse. Users who experience sleep disruption may switch to morning dosing while remaining fasted.

Tesamorelin Reconstitution

The following example uses a 10mg vial with 2mL of bacteriostatic water.

10mg Vial

BAC Water

2mL

Concentration

5mg/mL

1mg

20 units on a U-100 insulin syringe

2mg

40 units on a U-100 insulin syringe

Reconstitution Calculator

Handling Notes

Mixing

Add bacteriostatic water and gently swirl until dissolved

Storage

Store at room temperature, 68–77°F (20–25°C), in a dark cabinet

Do Not

Do not refrigerate or freeze after reconstitution

Use Window

Use within 7 days; research-vial stability may be shorter

Discard

Discard if cloudy, thickened, gel-like, discolored, or particulate

Cold temperatures can cause physical aggregation rather than chemical breakdown. Approved tesamorelin uses hydroxypropyl betadex to limit clumping, while research vials may not. Standard peptide purity testing does not measure aggregation.

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Reduced waist measurement and abdominal fullness are commonly reported over 3–6 months.
The strongest body-composition reports usually come from users running the full 2mg daily protocol.
Improved sleep often appears within 2–4 weeks.
Recovery benefits are commonly noticed after IGF-1 stabilizes.
Some users report improved muscle tone while losing abdominal fat.
Morning dosing often resolves sleep disruption.

Negative Reports

Injection-site redness, itching, and flushing can be more pronounced than with CJC-1295 or Ipamorelin.
Cost is a major complaint because daily dosing consumes community vials rapidly.
Water retention, joint discomfort, tingling, or carpal-tunnel-like symptoms sometimes limit dosing.

Stacking & Synergy

Potential Tesamorelin pairings and tracking context

Relevant Combinations

Tesamorelin + Ipamorelin

The most common GH-axis pairing. Tesamorelin supplies the GHRH signal while Ipamorelin activates the ghrelin receptor, potentially strengthening the same fasting-window pulse.

Tesamorelin + GLP-1 Agonist

Often used when appetite control and visceral-fat reduction are separate goals. Track glucose, protein intake, lean mass, edema, and overall rate of weight loss.

What to Avoid

Do not combine with direct growth hormone injections. Administering exogenous growth hormone while using a GHRH analog creates conflicting signals. The exogenous GH triggers negative feedback through somatostatin, which suppresses the pituitary response to tesamorelin.

Free with login

Track in Journal

Track Tesamorelin with the markers that matter most for this compound.

Waist measurement and abdominal fullness.
Body weight, lean-mass trend, and glucose.
Sleep quality, recovery, edema, and joint symptoms.

Start Tracking

Common Questions

Tesamorelin dosing and results

How long before users notice changes?

Sleep and recovery changes may appear within the first few weeks, while measurable waist and body-composition changes are more commonly discussed after 8–12 weeks of consistent use.

Does tesamorelin require fasting?

Fasted bedtime dosing is the dominant community approach because elevated insulin can blunt the desired GH pulse. Morning fasted dosing is a practical alternative when bedtime use disrupts sleep.

Do the visceral-fat benefits persist after stopping?

Clinical extension data found that visceral fat tended to return after tesamorelin was discontinued. Long-term results therefore depend on continued treatment, metabolic health, training, nutrition, and the reason therapy was started.

Safety Notes

Side effects, contraindications, and precautions

Tesamorelin Side Effects

Injection-site reactions and fluid-retention-related symptoms are the most commonly reported adverse effects.

Tesamorelin raises GH and IGF-1. Monitor glucose, IGF-1, edema, joint symptoms, and signs of carpal tunnel, especially during long-term use.

In Published Research

Common: injection-site redness, itching, pain, swelling, and flushing.
Possible: edema, joint pain, myalgia, paresthesia, and carpal-tunnel symptoms.
Temporary fasting-glucose increases have occurred and require monitoring.

What Users Report

Injection-site reactions lasting 10–20 minutes are common.
Sleep disruption may improve by switching to morning dosing.
Rare hypersensitivity symptoms require immediate discontinuation.

Tesamorelin Contraindications and Precautions

Do Not Use If You Have

Active cancer or a history of malignant tumor without specialist approval.
Pituitary disease, pituitary surgery, pituitary tumor, or head/brain radiation history.
Known hypersensitivity to tesamorelin or formulation ingredients.
Pregnancy.

Use Caution With

Diabetes, prediabetes, insulin resistance, kidney disease, or liver disease.
Heart disease, recent cardiac surgery, migraines, epilepsy, asthma, or adrenal disease.
Edema, sleep apnea, joint pain, or carpal-tunnel symptoms.

Drug Interactions

Do not combine with direct growth hormone without specialist management. Estrogen therapy may alter response, glucocorticoids may counteract effects, and diabetes medications may require adjustment.

Monitoring

Monitor IGF-1, fasting glucose or HbA1c, waist measurement, edema, joint symptoms, injection reactions, and liver or kidney status when relevant.

Regulatory Status

Tesamorelin is FDA approved as Egrifta for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Other body-composition uses are off-label.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Tesa has carved out a real niche in our fat-loss and body recomp stacks because it’s a targeted GHRH analog that reliably boosts natural GH pulses, especially effective for chipping away at stubborn visceral belly fat.

The strongest reports we see — and what matches our n=1 experience — are noticeable reductions in visceral adipose tissue, improved body composition, and better overall metabolic feel without the same intensity of sides you get from straight GH or some other secretagogues. It pairs nicely with Ipamorelin or Retatrutide for that extra edge on the midsection.

Biggest weakness is still the weight on your wallet (it's expensive) and the fact that most of the heavy data comes from HIV-related lipodystrophy studies rather than healthy athletes or biohackers doing long-term runs. Long-term safety in non-clinical populations isn’t fully mapped out.

We run it as a smart adjunct in a recomp protocol alongside proper diet, training, and other peptides — not a standalone magic bullet. If the cost is a problem, get CJC-1295 no DAC / Ipamorelin blend.